Page 9 - Landscape SA Issue 107

FEATURE

CILO CybIN’S DEVELOPMENTS

IN THE CANNAbIS INDUSTRy

In this 11th article on cannabis in Landscape SA, Johann

Slabber, Executive Director and Head of Business
Development at Cilo Cybin Pharmaceutical, provides
the company’s latest updates and developments in the
industry.

ilo Cybin believes that the world idea of the composition of such products,
is entering a new era, where nor what they are consuming.”
Cpersonalised health care is a primary
focus and where health and wellbeing There are two main categories of poor
must be individualised with intelligently quality medicines, namely sub-standard
targeted interventions. Slabber says the and counterfeit. The former arises as a result
company is focussed on the three pillars of lack of expertise, poor manufacturing
of health, performance and longevity. practices or insufficient infrastructure,
“Cannabis is in fact the smallest part of the whereas the latter may contain no active
company, and of what will come in the near ingredients, incorrect ingredients or toxins Johann slabber, executive director and head of
future,” he affirms. supplied by illegal routes. business development at Cilo Cybin

Having acquired both its cultivation and Slabber says that through Cilo Cybin’s Good health, performance and longevity. This has
manufacturing licenses for cannabis, Cilo Manufacturing Practice (GMP) standards, not previously been possible.
Cybin is now heading towards listing on the they want to provide their consumers with
Johannesburg Stock Exchange (JSE) early in security and consistency in their products. Biohacking is the constant pursuit of better
2022. “We have various research institutes, health, performance and longevity through
dosing and formulation experts who have the use of apps, technologies, devices
In addition, they will be launching their years of experience working with doctors and supplementation. Biotechnology
first line of manufactured products on the dosing and treatment of acute and and pharmaceutical companies both
into the South African retail market by chronic conditions. Our panel of doctors produce medicines, but those made by
December 2021, focussing on high quality, will ensure that products are specifically biotechnology companies are derived from
premium cannabis products. In the fast formulated for patients in order to provide living organisms, whereas those made by
developing cannabis industry, access to individualised care and treatment.” He pharmaceutical companies generally have
quality products is especially difficult, and adds that the buying and prescribing of a chemical basis.
Slabber warns: “With the rapid evolvement products is just one step of the approach,
of the industry and massive demand, but that monitoring and reporting thereof Slabber concludes: “We are excited to have
there is huge potential for the spread of is much more crucial. been featured on Bloomberg News and this
poor quality products before adequate is just the start of more media exposure
detection and interventions are possible. The company combines biohacking, biotech to come. Since August 2021, we have
Many people use illegally supplied and pharmaceutical methodologies to appeared in over 100 media outlets, having
products that have not followed the right deliver holistic and individualised solutions planned and developed our approach for
processes, and the end consumer has no that facilitate insight into their customers’ the past three years.” n

Landscape SA • Issue 107 2021 7